Aktis Oncology, Inc. (AKTS) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$22.86

From 52W high−32.11%

Volume2.73M

Market cap$1.22B

P/E (TTM)—

P/S (TTM)121.0x

Div yield—

Key dataSep 18, 2026

Open

$22.86

From 52W high

−32.11%

Volume

2.73M

Market cap

$1.22B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−9.1x

P/E (TTM)

—

RSI (14)

38.0

MomentumView details →

1D Return

−4.29%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−9.1x

EV/Sales

70.7x

P/S (TTM)

121.0x

P/B (TTM)

2.5x

ProfitabilityView details →

Gross Margin

84.78%

Net Margin

−727.04%

EBITDA Margin

−772.77%

ROE (TTM)

−15.09%

ROA (TTM)

−13.12%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+336.92%

EPS CAGR 3Y

+5.56%

EBITDA YoY

—

MomentumView details →

1D Return

−4.29%

YTD Return

—

1Y Return

—

RSI (14)

38.0

vs 50D SMA

−7.25%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

16.33x

Quick Ratio

16.33x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.44

EPS Surprise

−2.17%

Beats (12Q)

0/12

Next Q EPS Est

−$0.46

Avg Surprise (4Q)

−2.17%

Rev Surprise

25.44%

Financials snapshotView financials →

Revenue (TTM)

10.06M

Net Income (TTM)

−73.14M

Op. CF (TTM)

−75.29M

Next earningsNov 12, 2026 →

Latest newsMore news →

Aktis Oncology reported Q2 2026 collaboration revenue of $3.4 million, up from $1.6 million a year earlier, with a net loss of $24.1 million and cash and marketable securities of $517.3 million as of June 30, 2026.39d ago

Similar companies

Apnimed, Inc.APMD Replimune Group, Inc.REPL Alto Neuroscience, Inc.ANRO Maze Therapeutics, Inc.MAZE ST嘉必优688089.SH NewAmsterdam Pharma Company N.V.NAMSW Find similar companies →

Latest newsMore news →

Aktis Oncology reported Q2 2026 collaboration revenue of $3.4 million, up from $1.6 million a year earlier, with a net loss of $24.1 million and cash and marketable securities of $517.3 million as of June 30, 2026.39d ago